Literature DB >> 7824947

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.

J M Coffin1.   

Abstract

Several recent reports indicate that the long, clinically latent phase that characterizes human immunodeficiency virus (HIV) infection of humans is not a period of viral inactivity, but an active process in which cells are being infected and dying at a high rate and in large numbers. These results lead to a simple steady-state model in which infection, cell death, and cell replacement are in balance, and imply that the unique feature of HIV is the extraordinarily large number of replication cycles that occur during infection of a single individual. This turnover drives both the pathogenic process and (even more than mutation rate) the development of genetic variation. This variation includes the inevitable and, in principle, predictable accumulation of mutations such as those conferring resistance to antiviral drugs whose presence before therapy must be considered in the design of therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7824947     DOI: 10.1126/science.7824947

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  650 in total

1.  The molecular clock of HIV-1 unveiled through analysis of a known transmission history.

Authors:  T Leitner; J Albert
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

2.  Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.

Authors:  P L Sharma; C S Crumpacker
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

3.  A simple relationship between viral load and survival time in HIV-1 infection.

Authors:  R A Arnaout; A L Lloyd; T R O'Brien; J J Goedert; J M Leonard; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

4.  Adherence and drug resistance: predictions for therapy outcome.

Authors:  L M Wahl; M A Nowak
Journal:  Proc Biol Sci       Date:  2000-04-22       Impact factor: 5.349

5.  A new point mutation (P157S) in the reverse transcriptase of human immunodeficiency virus type 1 confers low-level resistance to (-)-beta-2',3'-dideoxy-3'-thiacytidine.

Authors:  R A Smith; G J Klarmann; K M Stray; U K von Schwedler; R F Schinazi; B D Preston; T W North
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

6.  Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy.

Authors:  N M Ferguson; F deWolf; A C Ghani; C Fraser; C A Donnelly; P Reiss; J M Lange; S A Danner; G P Garnett; J Goudsmit; R M Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

7.  Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy.

Authors:  E Quiros-Roldan; S Signorini; F Castelli; C Torti; A Patroni; M Airoldi; G Carosi
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

8.  Estimating relative fitness in viral competition experiments.

Authors:  A F Marée; W Keulen; C A Boucher; R J De Boer
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

9.  HIV therapy: managing resistance.

Authors:  D Wodarz; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

10.  Comparison of sequencing by hybridization and cycle sequencing for genotyping of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  G J Hanna; V A Johnson; D R Kuritzkes; D D Richman; J Martinez-Picado; L Sutton; J D Hazelwood; R T D'Aquila
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.